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Structured summary 
Aims  
This study aims to determine if potentially inappropriate prescribing (PIP) is associated with 
increased healthcare utilisation, functional decline and reduced quality of life (QoL) in a community-
dwelling older cohort. 
Method 
This prospective cohort study included participants aged ≥65 years from The Irish Longitudinal Study 
on Ageing (TILDA) with linked administrative pharmacy claims data who were followed up after two 
years. PIP was defined by the Screening Tool for Older Persons Prescriptions (STOPP) and Screening 
Tool to Alert doctors to Right Treatment (START). The association with number of emergency 
department (ED) visits and GP visits reported over 12 months was analysed using multivariate 
negative binomial regression adjusting for confounders. Marginal structural models investigated the 
presence of time-dependent confounding. 
Results 
Of participants followed up (n=1,753), PIP was detected in 57% by STOPP and 41.8% by START, 
21.7% reported an ED visit and 96.1% visited a GP (median 4, IQR 2.5-6). Those with any STOPP 
criterion had higher rates of ED visits (adjusted incident rate ratio (IRR) 1.30, 95% confidence interval 
(CI) 1.02-1.66) and GP visits (IRR 1.15, 95%CI 1.06-1.24). Patients with two or more START criteria 
had significantly more ED visits (IRR 1.45, 95%CI 1.03-2.04) and GP visits (IRR 1.13, 95%CI 1.01-1.27) 
than people with no criteria. Adjusting for time-dependent confounding did not affect the findings. 
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Conclusions 
Both STOPP and START were independently associated with increased healthcare utilisation and 
START was also related to functional decline and QoL. Optimising prescribing to reduce PIP may 
provide an improvement in patient outcomes.  
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Section 1: What is already known about this subject:  
 Potentially inappropriate medicines and potential prescribing omissions are common issues 
in older people.  
 Evidence of a link between these process measures of care and patient outcomes is 
important. 
 Many studies to date have been hospital-based and cross-sectional and evidence of an effect 
on patient-centred outcomes is less clear. 
Section 2: What this study adds: 
 In this community-dwelling older cohort, potentially inappropriate medicines were 
associated with increased emergency departments and GP visits. 
 Patients with multiple potential prescribing omissions had higher healthcare utilisation, 
increased chance of functional decline and reduced quality of life. 
 Optimising treatment to address potentially inappropriate prescribing may improve 
outcomes for older people 
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Introduction 
Older people are particularly vulnerable to adverse effects from medicines, partly due to 
pharmacokinetic and pharmacodynamic changes in ageing, and also because multimorbidity and 
complex drug regimens involving multiple medicines (polypharmacy) are common in this age 
group.[1–3] This has led to concerns regarding potentially inappropriate prescribing (PIP) in older 
people, including both errors of commission and omission.[4] The first form of PIP refers to 
potentially inappropriate medicines (PIMs), the use of medicines in circumstances where the risks 
outweigh the benefits or where a safer or better alternative exists. The second form of PIP is 
potential prescribing omissions (PPOs), medications which are clinically indicated for a patient not 
being prescribed. A number of explicit criteria have been developed to identify PIP and two 
commonly used measures are the Screening Tool for Older Persons’ Prescriptions (STOPP) which 
focuses on PIMs, and the Screening Tool to Alert doctors to Right Treatment (START) to screen for 
PPOs. [5] 
While STOPP and START can be considered process measures of medication safety,[6] it is important 
to establish that such prescribing does have an effect on patient outcomes, such as adverse drug 
events (ADEs), hospitalisations or quality of life (QoL). A number of studies have assessed the 
association of STOPP PIMs with such outcomes; however the impact of START PPOs on patients has 
received little attention.[7] Much of this research has been cross-sectional with limited capacity to 
determine the prospective relationship of PIMs and PPOs with patient outcomes. It is difficult to 
establish whether an association is causal using such study designs due to potential bias and 
confounding. Longitudinal cohort studies provide a more robust method to assess the impact of 
medication exposure as they can account for confounding by time-varying factors using appropriate 
methods and may allow for inference of causal effects.[8] 
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The aim of this study is to determine the association of potentially inappropriate prescribing 
detected by STOPP and START with healthcare utilisation, functional decline and QoL in a cohort of 
community-dwelling people aged ≥65 years in a longitudinal study. 
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Methods 
Study design 
This study included participants from The Irish Longitudinal Study on Ageing (TILDA), a nationally-
representative cohort study charting the health, economic and social circumstances of community 
dwellers aged ≥50 years. Some TILDA participants also consented to use of their administrative 
pharmacy claims data from the Health Service Executive Primary Care Reimbursement Service (HSE-
PCRS). Participants were included in the present study if they were aged ≥65 years at baseline TILDA 
interview, had been followed up after two years, were eligible for the General Medical Services 
(GMS) scheme and provided an identifier which was successfully linked to their pharmacy claims 
data. The GMS scheme provides free health services and prescribed medicines to eligible persons in 
Ireland, however a small monthly co-payment of €0.50 per prescription item has applied since 
October 2010. Eligibility for the GMS scheme is based on means testing, although all people aged 
over 70 were eligible until December 2008 when a higher income threshold was introduced for this 
age group compared to the general population. However approximately 96% of this age group were 
still eligible in 2012.[9] The STROBE standardised reporting guidelines for cohort studies have been 
followed in the reporting of this research.[10] 
Data collection for TILDA is conducted in waves every two years, including a face-to-face interview 
and self-completion questionnaire. Baseline data collection was carried out between 2009 and 2011 
and participants were followed up from 2012 to 2013. Medication dispensing data were extracted 
from the HSE-PCRS pharmacy claims database for each participant in the present study from 15 
months before the date of their TILDA baseline interview up to their follow-up interview to 
determine PIP exposure and all data were anonymised after extraction. Ethical approval for TILDA 
has been granted by Trinity College Dublin Faculty of Health Sciences research ethics committee.  
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Outcomes 
The primary outcome under investigation was healthcare utilisation, including both hospital 
emergency department (ED) visits and general practitioner (GP) visits. Healthcare utilisation was 
assessed during TILDA interview by asking participants in the previous 12 months did they visit a 
hospital ED as a patient, and about how often they visited their GP.  Regression models were fitted 
for ED visits and GP visits separately using the numbers of visits reported by participants in the 12 
months preceding their follow-up interview as the dependent variables. 
Two secondary outcomes were also analysed. The first was decline in physical functioning. Physical 
functioning is assessed during TILDA interview by asking participants if they have difficulty doing any 
of six named Activities of Daily Living (ADLs) due to a health or memory problem (including dressing, 
eating, and using the toilet). The outcome variable used was binary, classified as an increase in the 
number of ADLs a participant reported difficulty with between baseline and follow-up (functional 
decline) or no increase (no decline). Secondly QoL was investigated, which was assessed in the TILDA 
self-completion questionnaire using the CASP (Control, Autonomy, Self-Realisation, Pleasure), a 
measure designed for use in middle-aged and older people. In this analysis, participants’ QoL score 
at follow-up measured using the CASP-R12, a revised 12 item version of CASP with a possible range 
from 0 (worst QoL) to 36 (best), [11] was included as the continuous outcome variable. 
Exposure 
Exposure to PIMs measured by STOPP and PPOs measured by START was determined in this cohort 
of TILDA participants with linked pharmacy claims data and was reported previously.[12] Briefly, 45 
of 65 (69 %) STOPP criteria and 15 of 22 (68 %) START criteria were applied to determine the 
prevalence of PIP in the 12 months preceding baseline and follow-up interviews of TILDA (applicable 
criteria are listed in Table S1). The number of criteria that a participant was exposed to in each time 
period was determined separately for both screening tools. Exposure to STOPP for each participant 
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in the 12 months preceding outcome measurement and START exposure were included as the two 
main independent variables of interest. 
Statistical analysis 
Negative binomial regression models for the reported number of ED visits in 12 months and number 
of GP visits in 12 months were fitted, including two binary variables for the presence of any STOPP 
criteria and any START criteria (Model 1). Further analysis investigated a dose-response relationship 
by replacing these binary variables with categorical variables for 0, 1, or ≥2 criteria (Model 2). 
Results are presented as incident ratio ratios (IRR) with 95% confidence intervals (CI). This approach 
was then used for the secondary outcomes of functional decline using logistic regression models and 
QoL using linear regression models. Results of these analyses are presented as odds ratios (OR) and 
β regression coefficients respectively, with 95% CI.  Models were adjusted for age group, gender, 
level of educational attainment as a measure of socicoeconomic status, living arrangements, number 
of repeat medicines and number of doctor-diagnosed chronic conditions (detailed variable 
description in Table S2). Specific covariates were also adjusted for in each model relating to the 
outcome of interest, for example, private health insurance status and number of ED/GP visits 
reported at baseline interview in the analysis of healthcare utilisation. The possibility of an 
additional effect in individuals exposed to both PIMs and PPOs was assessed by the addition of an 
interaction term to each model and likelihood ratio tests were used to evaluate if this improved 
model fit. 
The impact of time-dependent confounding (by number of regular medicines or chronic conditions 
for example) was investigated using marginal structural models (MSMs), a two-step estimation 
strategy which separates confounding control for covariates that vary with time from parameter 
estimation.[8,13]  For each participant two weights were calculated, (i) stabilised inverse probability 
weights, the inverse of the probability of having the PIP exposure they did conditional on past PIP 
exposure and covariate history (including measurements from both baseline and follow-up), and  (ii) 
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censoring weights, the probability of remaining uncensored given past PIP exposure and covariate 
history. Weighted regression analyses (i.e. MSMs) were performed using the product of these 
weights for each outcome for STOPP PIM exposure and separately for START PPO exposure, 
adjusting for baseline covariates only. Statistical significance was assumed at p<0.05. Analyses were 
performed using Stata version 13 (Stata Corporation, College Station, TX, USA). 
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Results 
Participant inclusion in this study is shown in Figure 1 and a description of these individuals is 
included in Table 1. Those followed up (n=1,753) were mainly female (54.5%), had a mean age of 
76.5 years (standard deviation (SD) 6), a median of 6 regular dispensed medicines and 3 reported 
doctor-diagnosed chronic conditions. Regarding PIP, 57% of participants had a STOPP PIM in the 12 
months preceding follow-up (of these 30.1% had one and 26.9% had two or more PIMs) and the 
prevalence of START PPOs was 41.8% (with 29.2% having one PPO and 12.6% having multiple 
PPOs).[12] The most common STOPP criteria in the cohort were proton pump inhibitors at maximal 
dose for >8 weeks, aspirin with no history of coronary, cerebral or peripheral arterial symptoms or 
occlusive arterial event, and non-steroidal anti-inflammatory drugs (NSAIDs) with moderate to 
severe hypertension, while prevalent START omissions were calcium and vitamin D supplements in 
osteoporosis and anticoagulation in cases of atrial fibrillation or arrhythmia.[12] The percentage of 
individuals with both STOPP and START criteria was 24.8%.  
In the 12 months preceding follow-up interview, 16.1% of participants reported one ED visit, 3.8% 
reported two visits and 1.8% reported three or more while 96.1% of participants reported visiting a 
GP (median 4 visits, interquartile range (IQR) 2.5-6). Results of the healthcare utilisation analysis are 
presented in Table 2. In the multivariate model for ED visits adjusted for covariates, presence of any 
STOPP PIM was significantly associated with higher rates of visits while the presence of a START PPO 
was not significantly associated. When number of criteria was considered, there was a statistically 
significant increase in the rate of ED visits for those with two or more STOPP criteria (adjusted IRR 
1.42, 95% CI 1.06, 1.91) as well as for multiple START criteria (adjusted IRR 1.45, 95% CI 1.03, 2.04) 
relative to those with no criteria. For GP visits, having any STOPP PIM was associated with an 
increased rate of visits and having any PPO determined by START was not associated with a 
significant increase. In the model including number of criteria, the relationship of STOPP persisted 
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regardless of number of PIMs while two or more START PPOs were also significantly associated with 
increased GP visits (adjusted IRR 1.13, 95% CI 1.01, 1.27). 
Difficulties with ADLs were reported by 7.7% of participants at baseline and 8.3% of participants 
reported an increase in ADLs which caused difficulty at follow-up. In the multivariate logistic 
regression analysis having any START PPO was significantly associated with functional decline, with a 
larger effect in the dose-response model for those with multiple criteria (adjusted OR 2.06, 95% CI 
1.25, 3.39), however no evidence of an effect due to STOPP was found (Table 3). CASP-R12 scores at 
follow-up ranged from 5 to 36 (mean 26.2, SD 5.2). Multivariate linear regression found that neither 
presence of any STOPP nor any START criteria was significantly associated with CASP-R12 score (  
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Table 4). In Model 2, exposure to two or more START PPOs was associated with a small but 
statistically significant reduction in QoL (adjusted β coefficient -1.05, 95% CI -1.83, -0.26). 
Variables for the interaction between STOPP and START showed no statistically significant 
association (p > 0.05) with any of the outcomes and likelihood ratio tests provided no evidence of 
improved model fit and therefore, interactions terms were not included. In the MSMs analysis 
weighted by the inverse probability of exposure to a STOPP PIM (binary), and the probability of 
censoring to account for loss to follow-up at Wave 2, the IRR for ED visits decreased in magnitude 
and became marginally non-significant (adjusted IRR 1.27, 95% CI 0.99, 1.64) and for GP visits the 
estimate also decreased slightly, but remained significant. For START, the adjusted odds ratio for 
functional decline increased slightly to 1.61 (95% CI 1.10, 2.34) in the MSM which may suggest a 
degree of confounding by indication by a time-dependent covariate. Results from the MSMs and 
standard analyses for each outcome are presented in Table S3. 
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Discussion 
Older people in this study who were prescribed a STOPP PIM visited ED and their GP more often (for 
those with two or more PIMs, 42% and 16% increases in rate respectively), however no evidence of a 
relationship with functional decline and QoL was found. Participants with multiple PPOs had higher 
rates of healthcare utilisation (45% higher rate of ED visits and 13% more GP visits) and a small 
reduction in QoL. Having a START PPO was also associated with higher odds of functional decline 
over a two year period. Time-varying confounding did not appear to play a role in these associations. 
Studies on the impact of PIP have predominantly used cross-sectional or retrospective cohort 
designs so this study is one of few to examine the prospective relationship between STOPP and 
START and patient outcomes.[7] One prospective study of older hospitalised patients found a 
significant association between STOPP and avoidable ADEs,[14] and this is supported by other work 
on ADEs.[15–18] For the outcomes examined in the present study, the findings appear to be 
consistent with previous research, in that the weight of evidence supports an association of STOPP 
with hospital visits,[16,19] while fewer studies have shown an effect of STOPP on health-related 
QoL,[16] vulnerability,[19] and functional decline during hospital stay,[17] and START on non-
cardiovascular mortality.[20]  
All studies that have applied STOPP and START together in the same study have been hospital based 
with limited research on older populations in the primary care setting. Secondary analysis of data 
from a trial of a hospital pharmacist intervention found the only significant association was between 
number of STOPP criteria and number of medication-related hospital readmissions,[21] and that 
both STOPP and START had poor discriminative ability to identify older patients at risk of unplanned 
rehospitalisation or death.[22] A study of patients following hip fracture showed higher all-cause 
mortality among patients with a greater combined number of STOPP and START criteria.[23] A case-
control study of medication-related hospital admissions found an association with STOPP criteria 
and a composite of STOPP and START.[24] Studies that have used different measures of 
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inappropriate prescribing have also found an association with adverse outcomes in community-
dwelling older people, such as the Medication Appropriateness Index and high-risk prescribing 
classified using the Drug Burden Index.[25,26] A recent trial in general practice targeting high-risk 
use of NSAIDs and antiplatelet drugs significantly reduced not only the targeted prescribing but also 
the rate of hospitalisations for related adverse events.[27]  
Patients with either STOPP PIMs or START PPOs appear to have poorer outcomes, so incorporating 
review of these criteria into the care of older people and acting to rectify situations defined as 
inappropriate may benefit patients. When screening tools such as STOPP and START were 
developed, criteria were included if deemed by expert consensus to be potentially inappropriate 
with a marginally unfavourable risk-benefit ratio. This study provides evidence to support that this is 
the case and that there is an association between such prescribing and harm for patients. This is 
independent of the effect of number of medications, lending credence to the view that 
polypharmacy itself is not necessarily detrimental, but can be if it includes inappropriate 
prescribing.[28]  However given the limited time available to healthcare professionals to review and 
optimise treatment, the modest size of the effect of PIP should be considered when prioritising 
issues to spend time on with patients. If reviewing PIP can be incorporated easily into routine clinical 
practice, for example through clinical decision support systems or by streamlining explicit measures 
to focus on fewer high-risk criteria, using these screening tools may be an efficient way to avoid 
extra healthcare utilisation, functional decline or reduced QoL. Further research should consider the 
cost-effectiveness of such approaches and large-scale prospective cohort studies or economic 
modelling would provide evidence to identify the most clinically significant prescribing issues to 
focus on in practice. 
For patients who are identified as having PIP, discussing advantages and disadvantages of any 
medication change with the patient themselves is important. A recent trial in general practice to 
reduce PIP found that more changes were made when patients were present for medication 
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review.[29] Any discussion should put particular emphasis on the patient’s own priorities as they 
may place different weights on various benefits and risks. This is especially important when 
considering starting a new medication to address a PPO, as it may be preferable to both prescriber 
and patient  to not start a preventive treatment in advancing older age despite it being 
indicated.[30] Rigidly applying treatment guidelines can be ineffective as they do not take account of 
neither comorbidities nor patients’ preferences and evidence often comes from trials which did not 
include older patients.[31,32] This is in contrast to the process of addressing PIMs which may require 
consideration of stopping a medicine.[33] Both types of PIP present distinct challenges and different 
approaches may be needed to address potential errors of commission and omission.[34] 
Adjustment for time-dependent confounding using MSMs did not alter the results here, possibly 
because factors such as number of medicines were relatively time-stable over the study period. This 
may relate to therapeutic inertia, failure to start new drugs,[35] and conversely due to prescriber 
and patient reluctance to deprescribe treatments for fear of negative consequences.[36] Although 
MSMs may provide better evidence for causal relationships than conventional regression analyses, 
associations from longitudinal studies should also be interpreted in the context of other criteria for 
causation such as the Bradford Hill criteria.[37]  
This is one of the first longitudinal studies in the community setting to determine the prospective 
relationship between PIP and adverse outcomes. This robust design allowed for baseline differences 
to be accounted for and also addressed a number of criteria for inference of causality in 
epidemiological studies, including temporality and biological gradient.[37] Pharmacy claims data as 
used here may provide more reliable determination of medication exposure compared to self-
reported drug use.[38] However as dispensing data was used, it had to be assumed that dispensed 
medications were actually consumed and information on non-prescription medicines use was not 
available. 
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Limitations to the study were that a proportion of criteria from STOPP and START could not be 
applied to the data available in this study (see Table S1 for applicable criteria) and for those that 
were applied, this study did not have sufficient power to determine if any individual criteria were 
more strongly associated with adverse patient outcomes. The outcomes of healthcare utilisation and 
functional decline were patient reported rather than objective measures which may have affected 
accuracy, however the range of covariates adjusted for should have addressed any systematic 
reporting bias amongst participant subgroups.[39,40] The CASP-R12 is a measure of quality of life 
rather than health-related quality of life specifically and so may not have been sensitive to changes 
in the health status of participants. While this cohort was well characterised, there is still potential 
for the presence of unmeasured or unknown confounders. Although reverse causality could explain 
the relationships of START with adverse outcomes, i.e. preventive treatments being omitted in frailer 
patients with limited life expectancy who then experience functional decline and reduced QoL, 
controlling for baseline outcome differences and time-varying covariates should reduce this 
possibility.[8] 
PIP determined by STOPP and START was associated with adverse outcomes in a prospective older 
community-dwelling cohort. If application of these criteria can be integrated into routine medication 
review, they may help to support prescribers in optimising treatment and improve patient 
outcomes. Although such prescribing is only potentially inappropriate, the independent effects 
identified add weight to the suggestion that PIP is a marker of healthcare quality and patient safety 
and should be minimised if possible.  
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Figures 
 
Figure 1 Flow diagram of study participants The Irish Longitudinal Study on Ageing (TILDA). 
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Tables 
Table 1 Descriptive statistics for participants at baseline (Wave 1) and follow-up (Wave 2). 
 Baseline 
(Wave 1) 
(n=2051) 
Follow-up 
(Wave 2) 
(n=1753) 
Age (years, mean (SD)) 74.8 (6.17) 76.5 (6.04) 
Age group (years, n (%)) 
  65-74  1087 (53.0) 754 (43.0) 
≥ 75  964 (47.0) 999 (57.0) 
Sex (Female, n (%)) 1107 (54.0) 953 (54.4) 
Number of repeat drug classes (median (IQR)) 5 (3-8) 6 (3-9) 
Number of reported conditions (n (%)) 
  0 214 (10.4) 88 (5.0) 
1 423 (20.6) 268 (15.3) 
2 498 (24.3) 370 (21.1) 
3 or more 916 (44.7) 1027 (58.6) 
Level of education attainment (n (%)) 
  None/primary 1056 (51.5) 879 (50.2) 
Secondary 642 (31.3) 565 (32.3) 
Third/higher 351 (17.1) 308 (17.6) 
Living arrangements (n (%)) 
  Living alone 718 (35.0) 626 (30.5) 
Living with spouse 965 (47.1) 793 (38.7) 
Living with others 368 (17.9) 632 (30.8) 
Private health insurance (n (%)) 891 (43.4) 760 (43.4) 
Diagnosed mental health condition (n (%)) 129 (6.3) 157 (9.0) 
Any hospital admission (n (%)) 354 (17.3) 366 (20.9) 
Moderate activity (n (%)) 799 (39.0) 751 (42.8) 
Depressive symptoms (n (%))* 
  None  1172 (58.2) 1248 (74.9) 
Sub-clinical 613 (30.4) 277 (16.6) 
Clinical 230 (11.4) 141 (8.5) 
Social participation (n (%)) 943 (46.0) 826 (47.1) 
*Depressive symptoms measured by Centre for Epidemiological Studies Depression scale missing for 
36 participants at baseline and 87 participants at follow-up. 
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Table 2 Number (percentage) with an emergency department (ED) visit and mean (standard 
deviation) GP visits the 12 months preceding follow-up by subgroup and adjusted incident rate ratios 
(95% CI) for ED visits (n=1,748) and GP visits (n=1,741) 
  
n (%)  
Emergency department visits 
Adjusted IRR (95% CI)a 
  Model 1b Model 2c 
Any STOPP PIM (vs none) 246 (25.6) 1.30 (1.02, 1.66)* - 
Number of STOPP PIMs    
0 (reference) 134 (17.0)   
1 121 (22.4) - 1.23 (0.94, 1.62) 
≥2  125 (29.6) - 1.42 (1.06, 1.91)* 
Any START PPO (vs none) 174 (26.1) 1.23 (0.98, 1.53) - 
Number of START PPOs    
0 (reference) 206 (19.0)   
1 118 (24.3) - 1.15 (0.90, 1.46) 
≥2 56 (30.9) - 1.45 (1.03, 2.04)* 
  
Mean (SD) 
GP visits 
Adjusted IRR (95% CI)a 
  Model 1b Model 2c 
Any STOPP PIM (vs none) 6.3 (6.4) 1.15 (1.06, 1.24)* - 
Number of STOPP PIMs    
0 (reference) 4.5 (4.9)   
1 5.9 (6.3) - 1.14 (1.05, 1.25)* 
≥2  6.8 (6.6) - 1.16 (1.06, 1.28)* 
Any START PPO (vs none) 5.9 (6.1) 1.04 (0.97, 1.12) - 
Number of START PPOs    
0 (reference) 5.2 (5.7)   
1 5.6 (5.8) - 1.01 (0.93, 1.09) 
≥2 6.9 (6.6) - 1.13 (1.01, 1.27)* 
a Adjusted for age group, gender, number of repeat drug classes, number of reported conditions, 
level of educational attainment, living arrangements, private health insurance status and number of 
ED/GP visits reported at baseline 
b PIP exposure assessed using binary variables for presence or absence of STOPP and START 
c PIP exposure assessed using categorical variables for presence of 0, 1 and ≥2 STOPP and START 
criteria 
* p < 0.05 
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 Table 3 Number (percentage) with an increase in ADL difficulties (functional decline) between 
baseline and follow-up by subgroup and adjusted odds ratios (95% CI) for functional decline 
compared to no functional decline (n=1,753) 
 
  
n (%) 
Functional decline  
Adjusted OR (95% CI)a 
  Model 1b Model 2c 
Any STOPP PIM (vs none) 110 (11.0) 1.23 (0.78, 1.92) - 
Number of STOPP PIMs    
  0 (reference) 35 (4.6)   
  1 45 (8.5) - 1.23 (0.75, 2.02) 
  ≥2  65 (13.8) - 1.25 (0.75, 2.06) 
Any START PPO (vs none) 84 (11.5) 1.55 (1.07, 2.25)d - 
Number of START PPOs    
  0 (reference) 61 (6.0)   
  1 50 (9.8) - 1.35 (0.89, 2.04) 
  ≥2 34 (15.4) - 2.06 (1.25, 3.39)d 
 a Adjusted for age group, gender, number of repeat drug classes, number of reported conditions, 
level of educational attainment, living arrangements, reporting diagnosis of a mental health 
conditions, reporting a hospital admission in the 12 months preceding follow-up and reporting 
moderate activity at baseline 
b PIP exposure assessed using binary variables for presence or absence of STOPP and START 
c PIP exposure assessed using categorical variables for presence of 0, 1 and ≥2 STOPP and START 
criteria 
* p < 0.05  
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Table 4 Mean (standard deviation) of CASP-R12 quality of life score at follow-up by subgroup and 
adjusted β coefficient (95% CI) for CASP-R12 score (n=986) 
  
Mean (SD) 
CASP-R12 score 
Adjusted β coefficient (95% CI)a 
  Model 1b Model 2c 
Any STOPP PIM (vs none) 25.5 (5.4) -0.26 (-0.81, 0.29) - 
Number of STOPP PIMs    
0 (reference) 27.0 (5.0)   
1 26.2 (5.1) - -0.21 (-0.81, 0.39) 
≥2  24.7 (5.5) - -0.45 (-1.16, 0.27) 
Any START PPO (vs none) 25.5 (5.4) -0.24 (-0.75, 0.26) - 
Number of START PPOs    
0 (reference) 26.7 (5.1)   
1 26.0 (5.2) - 0.08 (-0.48, 0.64) 
≥2 24.2 (5.7) - -1.06 (-1.84, -0.27)* 
 a Adjusted for age group, gender, number of repeat drug classes, number of reported conditions, 
level of educational attainment, living arrangements, level of depressive symptoms, reporting social 
participation and CASP-R12 score at Baseline 
b PIP exposure assessed using binary variables for presence or absence of STOPP and START 
c PIP exposure assessed using categorical variables for presence of 0, 1 and ≥2 STOPP and START 
criteria 
* p < 0.05 
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Supporting material 
Table S1 List of applicable criteria from STOPP and START used to determine exposure to PIMs and 
PPOs 
Physiological 
system 
Criteria 
STOPP  
Cardiovascular Digoxin at dose >125 μg/day 
 Loop diuretic for dependent ankle oedema only  
 Loop diuretic as first-line monotherapy for hypertension  
 Thiazide diuretic with a history of gout  
 Non-cardioselective β blocker with COPD 
 β blocker in combination with verapamil  
 Aspirin and warfarin in combination without histamine H2 receptor antagonist 
(except Cimetidine) or PPI 
 Dipyridamole as monotherapy for cardiovascular secondary prevention 
 Aspirin with history of PUD without H2 receptor antagonist or PPI 
 Aspirin at dose >150 mg/day  
 Aspirin with no history of coronary, cerebral or peripheral arterial symptoms or 
occlusive arterial event 
CNS TCAs with dementia  
 TCAs with glaucoma  
 TCAs with cardiac conductive abnormalities  
 TCAs with an opiate or calcium channel blocker 
 Long-term (>1 month), long-acting benzodiazepines  
 Long-term (>1 month) neuroleptics  
 Long-term (>1 month) neuroleptics in those with Parkinsonism  
 Phenothiazines in patients with epilepsy  
 Anticholinergics to treat extrapyramidal side-effects of neuroleptics  
 Prolonged use (>1 week) of first generation antihistamines  
Gastrointestinal Prochlorperazine or metoclopramide with Parkinsonism  
 PPI at full therapeutic dosage for >8 weeks 
Respiratory Theophylline as monotherapy for COPD  
 Systemic corticosteroids instead of inhaled corticosteroids in COPD  
 Nebulised ipratropium with glaucoma  
Musculoskeletal NSAID with history of PUD, unless with concurrent H2 receptor antagonist, PPI or 
misoprostol 
 NSAID with moderate-severe hypertension >160/100 mmHga 
 NSAID with heart failure  
 Long-term use of NSAID (>3 months) 
 Warfarin and NSAID together 
 NSAID with chronic renal failure 
 Long-term corticosteroids (>3 months) as monotherapy for rheumatoid 
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Physiological 
system 
Criteria 
arthrtitis/osteorarthritis  
Urogenital Bladder antimuscarinic drugs with dementia  
 Bladder antimuscarinic drugs with chronic glaucoma 
 α blockers in males with frequent incontinence 
Endocrine Glibenclamide or chlorpropamide with type 2 diabetes mellitus 
 Oestrogens with a history of breast cancer 
Falls risk Benzodiazepines in those prone to falls 
 Neuroleptic drugs in those prone to falls 
 First generation antihistamines in those prone to falls 
 Long-term opiates (>1 month) in those with recurrent falls  
Analgesia Use of long-term strong opiates as first line therapy for mild-moderate pain  
 Regular opiates for >2 weeks without concurrent use of laxatives  
Duplicates Any regular duplicate drug class prescription e.g. two concurrent opiates, NSAIDs, 
SSRIs, loop diuretics, ACE inhibitors, or other antidepressant 
  
START  
Cardiovascular Warfarin (or another oral anticoagulant) in the presence of chronic atrial 
fibrillation 
 Aspirin/clopidogrel with a history of atherosclerotic coronary, cerebral or 
peripheral vascular disease 
 Antihypertensive therapy where systolic blood pressure >160 mmHga 
 Statin therapy with a history of coronary, cerebral or peripheral vascular disease 
 ACE inhibitor with chronic heart failure 
 ACE inhibitor following acute myocardial infarction 
 β blocker with chronic stable angina 
Respiratory Regular inhaled β2 agonist or anticholinergic agent for mild to moderate asthma 
or COPD 
CNS L-DOPA in Parkinson’s with definite functional impairment 
 Antidepressant drug in the presence of moderate-severe depressive symptoms 
Musculoskeletal Bisphosphonates if taking oral corticosteroids for >3 months 
 Calcium and vitamin D supplement with osteoporosis 
Endocrine ACE inhibitor or ARB in diabetes with nephropathy 
 Antiplatelet therapy in diabetes mellitus if ≥1 major CV risk factor (hypertension, 
hypercholesterolaemia, smoking history) 
 Statin therapy in diabetes mellitus if ≥1 major CV risk factor 
Abbreviations: ACE: angiotensin converting enzyme, ARB: angiotensin II receptor blocker, COPD: 
chronic obstructive pulmonary disease, CV: cardiovascular, NSAID: non-steroidal anti-inflammatory 
drug, PPI: proton pump inhibitor, PUD: peptic ulcer disease, SSRI: selective serotonin reuptake 
inhibitor, TCA: tricyclic antidepressant 
a Hypertension defined using objectively measured blood pressure or self-reported hypertension 
diagnosis with antihypertensive medication  
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Table S2 Description of covariates adjusted for in multivariate regression models 
Variable Format Description of categories 
 Age group Binary 65-74 years (reference)  
≥ 75 years 
 Gender Binary Male (reference) 
Female 
 Number of repeat drug classesa Continuous N/A 
 Number of reported conditionsb Categorical 0 (reference) 
1 
2 
3 or more 
 Level of education attainment Categorical  None/primary (reference) 
Secondary 
Third/higher 
 Living arrangements Categorical Living alone (reference) 
Living with spouse 
Living with others 
 Private health insurance Binary No (reference) 
Yes 
 Number of ED visits at baseline Continuous N/A 
 Number of GP visits at baseline Continuous N/A 
 Diagnosed mental health conditionc Binary No (reference) 
Yes 
 Any hospital admission in 12 months 
pre follow-up 
Binary No (reference) 
Yes 
 Moderate physical activity at baseline Binary No (reference) 
Yes 
 Depressive symptomsd Categorical None (reference) 
Sub-clinical 
Clinical 
 Social participatione Binary No (reference) 
Yes 
 CASP-R12 score at baseline Continuous N/A 
a Number of medicines (defined by level 3 ATC code) dispensed in at least 3 months to a participant 
during the 12 months of PIP exposure measurement in HSE-PCRS (with an upper bound of 10 or 
more medicines). 
b The number of doctor-diagnosed chronic conditions reported by the participants at the TILDA 
interview from the following list: cardiovascular disease (heart attack, heart failure or angina), 
cataracts, hypertension, high cholesterol, stroke, diabetes, lung disease, asthma, arthritis, 
osteoporosis, cancer, Parkinson's disease, peptic ulcer, and hip fracture. 
c Reported a doctor-diagnosed emotional, nervous or psychiatric problem during TILDA interview 
d Level of symptoms screened by the Centre for Epidemiological Studies Depression scale (CES-D) in 
the self-completion questionnaire at follow-up. None corresponds to a CES-D score of 0-7, sub-
clinical to a score of 8-15, and clinical to a score of >15. 
e Reported social participation in any groups such as sports or social groups   
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Table S3 Comparison of adjusted parameter estimates (95% CI) for presence of any STOPP PIM and 
any START PPO from unweighted multivariate regression models and marginal structural (weighted) 
models  
 Unweighted 
analysis 
p Weighted analysis 
(MSM)a 
p 
STOPP     
ED visits (IRR (95% CI)) 1.31 (1.02, 1.67) 0.031 1.27 (0.99, 1.64) 0.063 
GP visits (IRR (95% CI)) 1.15 (1.06, 1.24) 0.001 1.15 (1.06, 1.25) 0.001 
Functional decline (OR (95% CI)) 1.21 (0.77, 1.89) 0.411 1.19 (0.71, 2.01) 0.499 
CASP-R12 score (β coeff (95% CI)) -0.26 (-0.81, 0.29) 0.353  -0.31 (-0.92, 0.30) 0.322 
START     
ED visits (IRR (95% CI)) 1.24 (0.99, 1.54) 0.063 1.26 (0.99, 1.60) 0.062 
GP visits (IRR (95% CI)) 1.04 (0.97, 1.12) 0.288 1.04 (0.95, 1.14) 0.406 
Functional decline (OR (95% CI)) 1.54 (1.06, 2.24) 0.024 1.61 (1.1, 2.34) 0.014 
CASP-R12 score (β coeff (95% CI)) -0.25 (-0.76, 0.26) 0.34  -0.05 (-0.58, 0.50) 0.858 
a Weighted by product of stabilised inverse probability of exposure and probability of remaining 
uncensored at follow-up 
